Abstract | INTRODUCTION: The advent of anti-CD20 monoclonal antibody (mAb) rituximab heralded a new era in the treatment of non-Hodgkin's lymphoma leading to significant improvements in outcome for patients. This unprecedented success has changed the mindset of the clinical community and catalyzed the interest in the pharmaceutical industry to develop the next-generation of antibodies and antibody conjugates in cancer. AREAS COVERED: EXPERT OPINION: Despite the large numbers of new anti-CD20 mAb currently undergoing clinical testing, improving on clinical efficacy of rituximab is a substantial challenge. Further improvements in outcome for patients will require rigorous testing in well designed clinical trials alongside the translation of new insights into mechanism of mAb action that lead to improvements in clinical efficacy.
|
Authors | Sam Mayes, Nick Brown, Tim M Illidge |
Journal | Expert opinion on biological therapy
(Expert Opin Biol Ther)
Vol. 11
Issue 5
Pg. 623-40
(May 2011)
ISSN: 1744-7682 [Electronic] England |
PMID | 21395497
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antibodies, Monoclonal
- Antineoplastic Agents
|
Topics |
- Antibodies, Monoclonal
(pharmacology, therapeutic use)
- Antineoplastic Agents
(pharmacology, therapeutic use)
- Humans
- Lymphoma, Non-Hodgkin
(drug therapy)
- Radioimmunotherapy
|